NEU.ASX: Trading Halt

Trading Halt

Stock	Neuren Pharmaceuticals Ltd (NEU.ASX)
Release Time	4 Feb 2026, 10:14 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Neuren Pharmaceuticals Requests Trading Halt

Key Points

Pending announcement on FDA feedback for NNZ-2591 in Pitt Hopkins syndrome and Hypoxic-ischemic encephalopathy
Trading halt to remain in place until earlier of open trade on Friday, 6 February 2026 or release of announcement
Halt requested to manage disclosure obligations and maintain orderly market

Full Summary

Neuren Pharmaceuticals Limited (ASX: NEU) has requested an immediate trading halt in its securities, pending the release of an announcement regarding US Food & Drug Administration (FDA) feedback on its NNZ-2591 drug for the treatment of Pitt Hopkins syndrome and Hypoxic-ischemic encephalopathy (HIE). The trading halt will remain in place until the earlier of the commencement of normal trading on Friday, 6 February 2026 or the release of the announcement by the company. Neuren has requested the trading halt to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the company's shares. The company confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.